Form 4: Sutro Biopharma Officer Boosts Stake

David Pauling, Chief Admin. Ofcr. & GC of Sutro Biopharma, acquired 12,504 shares of common stock, increasing his beneficial ownership.

Summary

• David Pauling, Chief Administrative Officer and General Counsel of Sutro Biopharma, Inc. (STRO), purchased common stock.
• The transaction occurred on October 15, 2025.
• Pauling acquired 12,504 shares of common stock at a price of $0.7992 per share.
• Following this transaction, Pauling beneficially owns a total of 71,737 shares of Sutro Biopharma common stock.
• The reported total includes 2,500 shares acquired through the company's Employee Stock Purchase Plan (ESPP), which are exempt under SEC Rules 16a3(f)(1)(i)(B) and 16b3(c).

Sentiment

Score: 7

Explanation: The acquisition of additional shares by a key executive indicates confidence in the company's future, which is generally a positive signal for investors.

Positives

• Insider buying by a key executive (Chief Admin. Ofcr. & GC) signals confidence in the company's future prospects.
• The acquisition of 12,504 shares represents a direct investment by management.
• Participation in the Employee Stock Purchase Plan (ESPP) further aligns management's interests with shareholders.

Negatives

• The filing itself does not contain any explicitly negative information.

Future Outlook

The filing does not provide forward-looking statements or guidance.

Industry Context

Insider purchases, such as this one by a senior executive, are often interpreted by the market as a positive signal, indicating management's belief that the company's stock is undervalued or that future performance will be strong. This aligns with general market sentiment that insider buying can precede positive stock performance.

Comparison to Industry Standards

• This is a standard insider transaction report (Form 4) and does not lend itself to direct comparison with specific companies or projects. However, the act of an executive increasing their stake is generally viewed favorably across industries, suggesting confidence in the company's trajectory.

Related Party Transactions

• The filing notes that 2,500 shares included in the total were acquired through the Issuer's Employee Stock Purchase Plan (ESPP), which is a common related-party transaction between a company and its employees.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive indicator of management confidence, potentially leading to increased investor interest or positive sentiment.
• Employees: The continued participation in the ESPP by a senior executive reinforces the value of employee stock ownership programs.

Key Dates

Recommendation

The insider purchase by a key executive is a positive signal, suggesting management's belief in the company's value. While not a definitive "buy" signal on its own, it provides a favorable data point that supports holding the stock, especially if other fundamental analyses are positive. It indicates internal confidence, which can be a precursor to future positive developments.

Keywords

Sutro Biopharma, STRO, insider trading, Form 4, David Pauling, stock purchase, common stock, beneficial ownership, executive, Chief Administrative Officer, General Counsel, SEC filing